Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 423.50M P/E - EPS this Y 31.70% Ern Qtrly Grth -
Income -51.5M Forward P/E -18.33 EPS next Y 38.40% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 40.24 EPS next 5Y - 52W High Chg -19.00%
Recommedations 1.70 Quick Ratio 0.23 Shares Outstanding 22.30M 52W Low Chg 106.00%
Insider Own 38.85% ROA -70.76% Shares Float 5.87M Beta 0.19
Inst Own 22.77% ROE - Shares Shorted/Prior 1.33M/582.13K Price 1.65
Gross Margin - Profit Margin - Avg. Volume 1,276,037 Target Price 39.91
Oper. Margin - Earnings Date May 13 Volume 1,001,706 Change -1.20%
About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics, Inc. News
04/15/24 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
04/10/24 Insiders are Piling into These 10 Healthcare Stocks in 2024
03/22/24 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
03/18/24 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
03/12/24 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
03/06/24 7 of the Best Speculative Stocks You Can Snag for Less Than $1
02/25/24 7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
02/14/24 Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments
02/14/24 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
01/31/24 Outlook Therapeutics® Doses First Subject in NORSE EIGHT
01/24/24 Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
01/23/24 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
12/22/23 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
12/19/23 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
12/06/23 Outlook Therapeutics® Announces Strategic Organizational Realignment
11/28/23 Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term
11/27/23 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
11/14/23 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe
11/09/23 12 Best Day Trading Stocks To Buy
11/02/23 Outlook Therapeutics® Provides Update on Type A Meetings with FDA
OTLK Chatroom

User Image intratio Posted - 6 hours ago

https://www.intratio.com/stock-forecast/OTLK Our statistical model assessed the market value of this company has a bad setup for the short run and won t present a long-term opportunity $OTLK

User Image pfelgueiras Posted - 20 hours ago

$OTLK - A sad news COO Terry Dagnon passed away on April 11, 2024 SOURCE: https://www.horancares.com/obituaries/terry-dagnon

User Image biostockhunter Posted - 1 day ago

$OTLK They are looking for partnerships in EU upon approval. Also merger and acquisitions...

User Image OnlyOneLife81 Posted - 1 day ago

$OTLK MMs playing their daily game until news.... pretty soon in May. However, we can see how volune went considerably down, and we can assume that acculation is also done. Waiting game as usual. Longs here are like: same old, nothing new...

User Image lixx2874 Posted - 1 day ago

$OTLK srsly, what the xxck this stock is doing.

User Image DNegs Posted - 2 days ago

$OTLK unlimited naked shares & still a 186m MC…absolutely pathetic bears…tick tock

User Image insiderbuyingselling Posted - 2 days ago

$OTLK new insider buying: 714286 shares. http://insiderbuyingselling.com/?t=OTLK

User Image basscat12 Posted - 2 days ago

$CXAI $OTLK $DBD $NBBK New Option Listings courtesy @marketchameleonwins

User Image Kylian7 Posted - 2 days ago

$OTLK On March 21, 2024, the Committee for Medicinal Products for Human Use (CHMP) issued a favorable opinion, recommending the approval of the medicinal product Lytenava for the treatment of neovascular (wet) age-related macular degeneration (nAMD). After thorough analysis, I have not found any cases where the EMA did not follow the CHMP's recommendation. There is therefore certainty that in approximately a month, OTLK will have a market value that will become a floor below which the value should not drop since the market will be secured. The question that many of us may be asking is why, despite the near certainty of obtaining this marketing authorization in Europe and given that the European market represents at least $1 billion in annual revenue, the market capitalization remains stuck at $200 million, and with the dilution effect to come on warrants at $300 million? What is your opinion on this matter?

User Image Kassianys Posted - 2 days ago

$OTLK 50$ PT! WOW!

User Image shark_finance Posted - 3 days ago

$OTLK no volume today

User Image Franca_ole Posted - 3 days ago

$OTLK On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lytenava, intended for treatment of neovascular (wet) age-related macular degeneration (nAMD). Hence Lytenava will be approved by the EC on 27.5.2024 at the latest. 100% https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava

User Image GenerallyGentle Posted - 4 days ago

$OTLK April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC , an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting offering expenses. In addition, Outlook Therapeutics has the potential to receive additional gross proceeds of up to $8 million upon the full cash exercise of the warrants issued in the private placement, before deducting offering expenses.

User Image Stock_Titan Posted - 4 days ago

$OTLK $OTLKW Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million https://www.stocktitan.net/news/OTLK/outlook-therapeutics-r-announces-closing-of-private-placement-of-5-0-5e1fyog660wg.html

User Image eagles215 Posted - 4 days ago

$OTLK

User Image Multi_Millions Posted - 5 days ago

$OTLK what should we expect this week? We may see low 8s or high 7s but in due time approval will come and it will be a total different game.

User Image Buylocal Posted - 5 days ago

$OTLK $93 million in dilution. I told you weeks ago. Say hello to $6-7.

User Image Britbox Posted - 6 days ago

$OTLK longs be like

User Image Britbox Posted - 6 days ago

$OTLK pre market is dead ☠️

User Image Waldo_III Posted - 1 week ago

$OTLK Yeah good thing.. Lol😂😂🤡🤡🤡🤡🤡🤡

User Image TwongStocks Posted - 1 week ago

$OTLK New prospectus updating their $100m ATM offering with BTIG. https://www.sec.gov/Archives/edgar/data/1649989/000110465924046793/tm2411708d2_424b5.htm The ATM offering was originally agreed to in May 2023. Since then, they raised $6,268,132 under that ATM. $93,731,868 remains. That ATM was filed pursuant to a $250m shelf registration from March 2021. That shelf registration expired and was replaced with a $300m shelf registration this year. As a result, they amended the remaining amount left under the ATM to file it pursuant to the new $300m shelf registration.

User Image GenerallyGentle Posted - 1 week ago

$OTLK ouch. first close below $8.75. looking lower from here folks until news

User Image eagles215 Posted - 1 week ago

$OTLK $40 target 😭😉

User Image GenerallyGentle Posted - 1 week ago

$OTLK S&P seems to be finding balance around 5140 to 5160 area even though it was a gap down. I have that area marked from wednesday as a watch for reaction area. either there will be buyers/support or it will liquidate longs if it breaks lower.

User Image Mountain_Sand_000 Posted - 1 week ago

$OTLK orders won’t fill at the current price levek

User Image Kassianys Posted - 1 week ago

$OTLK how is inflow?

User Image Happythefrog Posted - 1 week ago

$CISS interesting moves 🙌🙌🙌💎💎💎 $OTLK was similar r/s action to ^^ and made a great return 💹🐸

User Image eagles215 Posted - 1 week ago

$OTLK garbage

User Image Britbox Posted - 1 week ago

$OTLK

User Image GenerallyGentle Posted - 1 week ago

$OTLK wowsers that premarket spread is wide

Analyst Ratings
BTIG Buy Mar 27, 24
HC Wainwright & Co. Buy Mar 25, 24
Chardan Capital Buy Feb 15, 24
Guggenheim Buy Jan 25, 24
Brookline Capital Buy Jan 25, 24
Ascendiant Capital Buy Dec 29, 23
Capital One Overweight Dec 27, 23
HC Wainwright & Co. Buy Nov 3, 23
Chardan Capital Neutral Aug 31, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dagnon Terry Chief Operations Off.. Chief Operations Officer Apr 20 Sell 1.135 520,000 590,200 653,058 04/21/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 20 Sell 1.11 267,000 296,370 745,975 01/24/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 17 Sell 1.26 164,155 206,835 1,012,975 01/19/23
HILZINGER KURT J Director Director Oct 04 Buy 1.26 111,203 140,116 473,117 10/05/22
Dagnon Terry Chief Operating Offi.. Chief Operating Officer Jun 21 Buy 1.05 10,000 10,500 1,173,058 06/23/22
TRENARY C RUSSELL III CEO and President CEO and President Jun 21 Buy 1.06 19,925 21,120 54,925 06/23/22
HILZINGER KURT J Director Director Mar 01 Buy 1.69 27,708 46,827 273,117 03/03/22
HILZINGER KURT J Director Director Feb 24 Buy 1.53 47,160 72,155 245,409 02/28/22
HILZINGER KURT J Director Director Feb 22 Buy 1.47 175,132 257,444 198,249 02/23/22